PeLeMed
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
PeLeMed - overview
Established
2019
Location
Gwangju, -, South Korea
Primary Industry
Biotechnology
About
Founded in 2019 and based in Gwangju, South Korea, PeLeMed is a drug research and development company on cancer, nerve, immune diseases, and new drug development. In September 2026, PeLeMed raised KRW 5 billion in venture funding from new investors SGC Partners and GIST Holdings. Returning investor Samho Green Investment and other unspecified investors also participated in the round. The company will use the funding to advance the clinical development of its acute myeloid leukemia (AML) drug candidate, PLM-102, including its U.
S. Phase I trial, and to accelerate research and development of additional oncology pipeline assets.
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.pelemed.com/
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.